Related Experiment Video
Updated: Aug 11, 2026
Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration
Published on: January 20, 2014
Skeletal myoblast transplant in heart failure
Eugene K W Sim1, Shujia Jiang, Lei Ye
1Division of Cardiothoracic Surgery, National University of Singapore, Singapore. sursimkw@nus.edu.sg
Insights
Cellular cardiomyoplasty offers a promising new approach for treating heart failure after myocardial infarction. This technique involves grafting various cells, including stem cells, to repair cardiac muscle and improve ventricular function.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Molecular Biology
Background:
- Ischemic heart disease (IHD) leading to heart failure post-myocardial infarction presents significant treatment challenges.
- Current options like heart transplantation and mechanical assist devices have limitations, including supply issues and high costs.
- Dynamic cardiomyoplasty has demonstrated limited clinical success.
Purpose of the Study:
- To explore novel strategies for cardiac muscle repair at molecular and cellular levels.
- To investigate cellular cardiomyoplasty as a method to augment ventricular function.
- To assess the potential of intracardiac cell grafting for treating heart failure secondary to myocardial infarction.
Main Methods:
- Utilizing insights into myocardial disease pathogenesis and molecular biology advancements.
- Developing cellular-level strategies for cardiac muscle regeneration.
- Employing intracardiac cell grafting techniques.
Main Results:
- Recent progress enables new molecular and cellular strategies for cardiac repair.
- Cellular cardiomyoplasty through intracardiac cell grafting is a developing therapeutic avenue.
- Potential cell sources include adult and fetal cardiomyocytes, stem cells, and autologous skeletal myoblasts.
Conclusions:
- Cellular cardiomyoplasty represents a promising strategy for enhancing ventricular function.
- Intracardiac cell grafting holds potential for treating heart failure post-myocardial infarction.
- Further research into cell types and delivery methods is warranted for clinical application.
Abstract:
Despite recent advances in the prevention and treatment of ischemic heart disease (IHD), treatment of patients with heart failure secondary to myocardial infarction remains a therapeutic challenge. Heart transplantation has emerged as a viable option but is fraught with problems of supply. Mechanical assist devices are extremely expensive and dynamic cardiomyoplasty has shown only limited success in the clinical setting. Recent insights into the pathogenesis of myocardial diseases and the progress made in the field of molecular biology have resulted in the development of new strategies at molecular as well as cellular levels for cardiac muscle repair. One such strategy is to augment ventricular function by means of cellular cardiomyoplasty through intracardiac cell grafting using adult and fetal cardiomyocytes, stem cells, and autologous skeletal myoblasts.
